Latest News

Jul 14th, 2008
SuppreMol closes EUR 15.7 M Series B Financing Round

Sep 12th, 2007
Orphan Drug Status for ITP

Mar 26th, 2007
Qualification of SuppreMol as an SME by the EMEA

Meet Us At

September 10-14, 2008
6th International Congress on Autoimmunity Porto, Portugal

September 16-19 2008
bioLOGIC Europe 2008 Geneva, Switzerland

Downloads

Corporate Fact Sheet

Press Resources

Video on SuppreMol

Unlocking the therapeutic potential of Fc-Receptors in autoimmune diseases

SuppreMol GmbH is a private biotechnology company located in Martinsried near Munich, Germany, and is focused on the development of novel therapeutics for the treatment of autoimmune diseases. In particular the Company is focused on the development of soluble Fcγ-Receptors (sFcRs) which are recombinant autologous therapeutic proteins endowed with a proven strong immunosuppressive potential. SuppreMol will develop sFcR as a therapeutic for autoimmune diseases such as Idiopathic Thrombocytopenic Purpura in the first instance and then Systemic Lupus Erythematosus, and Rheumatoid Arthritis. The Company promotes an additional program to develop an anti-FcγRIIb monoclonal antibody to target FcγR receptors. The Company was founded in 2002 as a spin-off from the Max-Planck-Institute of Biochemistry in Martinsried/Germany.

SuppreMol GmbH | Am Klopferspitz 19
82152 Martinsried / Munchen | Deutschland
t +49-89-309050 68-0 | f: +49-89-309050 68-68
e: info@suppremol.com